Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Arrhythmogenic Right Ventricular Cardiomyopathy
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 14 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Tenaya Therapeutics
- Last updated on ClinicalTrials.gov
- November 1, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Francisco · San Francisco, CA
Colorado · 1
- University of Colorado, Denver · Aurora, CO
Maryland · 1
- John Hopkins University School of Medicine · Baltimore, MD
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
New York · 1
- New York University · New York, NY
Ohio · 1
- Cleveland Clinic · Cleveland, OH
South Carolina · 1
- Medical University of South Carolina · Charleston, SC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.